Population pharmacokinetic evaluation with external validation and bayesian estimator of voriconazole in liver transplant recipients

Kelong Han, Robert Bies, Heather Johnson, Blair Capitano, Raman Venkataramanan

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objectives: The objectives of this study were to evaluate the pharmacokinetics of voriconazole in liver transplant patients, probe covariate effects on voriconazole pharmacokinetics, externally validate the model and explore limited sampling strategies (LSSs) using Bayesian approaches. Methods: Full pharmacokinetic profiles were collected within one oral dosing interval from 13 liver transplant patients.Nonlinearmixed-effects pharmacokineticmodels were developed usingNONMEMsoftware. The final model was internally evaluated using bootstrapping and visual predictive check (VPC), and externally validated by predicting additional samples from different patients that were not used for model building. Maximum a posteriori Bayesian estimators were developed to predict the area under the plasma concentration-time curve (AUC) using the validated final model as the a priori model, actual dosing record and covariate values as the input, and a fewconcentrations (limited sampling) as feedback information (LSS).Mean prediction error (MPE) and mean absolute prediction error (MAPE) were calculated for external validation and LSS. Results: A one-compartment model with an absorption lag time (tlag) adequately described the data. Population estimates of total clearance after oral administration (CL/F) and volume of distribution after oral administration (Vd/F) were 7.92L/h and 248 L, respectively. Values of CL/F, V d/F and tlag decreased with post-operative time and converged to stable levels in about 7 post-operative days. CL/F significantly decreased with increased international normalized ratio. Co-administration of pantoprazole, race and alanine aminotransferase were also significantly associated with pharmacokinetic parameters but ultimately excluded in the final model. VPC showed that most of the data fell within the 90%prediction interval and were symmetrically distributed around the median. Additional 52 samples from 19 patients were collected for external validation. MPE was 0.206 μg/mL (not significantly different from zero) and MAPE was 0.99 μg/mL. Compared with trough levels, LSS using two samples or one sample at a different time provided better MPE, MAPE and correlation (R2) between the observed and LSS-predicted AUC. Conclusions: The population model that was developed showed significant association of voriconazole pharmacokinetics with post-operative time and liver function, and was able to predict an independent external dataset. Our observations suggested a need for intravenous administration of voriconazole in the immediate post-operative period before an oral dose can be administrated. LSS using one sample appeared to be sufficient for reasonable AUC estimation.

Original languageEnglish
Pages (from-to)201-214
Number of pages14
JournalClinical Pharmacokinetics
Volume50
Issue number3
DOIs
StatePublished - 2011

Fingerprint

Pharmacokinetics
Liver
Area Under Curve
Population
Operative Time
Oral Administration
Transplants
International Normalized Ratio
Bayes Theorem
Alanine Transaminase
Intravenous Administration
Voriconazole
Transplant Recipients

Keywords

  • Antifungals
  • Dose-prediction
  • Liver-transplant
  • Pharmacokinetic-modelling
  • pharmacokinetics
  • Population-pharmacokinetics
  • Voriconazole

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Population pharmacokinetic evaluation with external validation and bayesian estimator of voriconazole in liver transplant recipients. / Han, Kelong; Bies, Robert; Johnson, Heather; Capitano, Blair; Venkataramanan, Raman.

In: Clinical Pharmacokinetics, Vol. 50, No. 3, 2011, p. 201-214.

Research output: Contribution to journalArticle

Han, Kelong ; Bies, Robert ; Johnson, Heather ; Capitano, Blair ; Venkataramanan, Raman. / Population pharmacokinetic evaluation with external validation and bayesian estimator of voriconazole in liver transplant recipients. In: Clinical Pharmacokinetics. 2011 ; Vol. 50, No. 3. pp. 201-214.
@article{8ea36c64bc0b4bffadf44a7a5fcd07b3,
title = "Population pharmacokinetic evaluation with external validation and bayesian estimator of voriconazole in liver transplant recipients",
abstract = "Objectives: The objectives of this study were to evaluate the pharmacokinetics of voriconazole in liver transplant patients, probe covariate effects on voriconazole pharmacokinetics, externally validate the model and explore limited sampling strategies (LSSs) using Bayesian approaches. Methods: Full pharmacokinetic profiles were collected within one oral dosing interval from 13 liver transplant patients.Nonlinearmixed-effects pharmacokineticmodels were developed usingNONMEMsoftware. The final model was internally evaluated using bootstrapping and visual predictive check (VPC), and externally validated by predicting additional samples from different patients that were not used for model building. Maximum a posteriori Bayesian estimators were developed to predict the area under the plasma concentration-time curve (AUC) using the validated final model as the a priori model, actual dosing record and covariate values as the input, and a fewconcentrations (limited sampling) as feedback information (LSS).Mean prediction error (MPE) and mean absolute prediction error (MAPE) were calculated for external validation and LSS. Results: A one-compartment model with an absorption lag time (tlag) adequately described the data. Population estimates of total clearance after oral administration (CL/F) and volume of distribution after oral administration (Vd/F) were 7.92L/h and 248 L, respectively. Values of CL/F, V d/F and tlag decreased with post-operative time and converged to stable levels in about 7 post-operative days. CL/F significantly decreased with increased international normalized ratio. Co-administration of pantoprazole, race and alanine aminotransferase were also significantly associated with pharmacokinetic parameters but ultimately excluded in the final model. VPC showed that most of the data fell within the 90{\%}prediction interval and were symmetrically distributed around the median. Additional 52 samples from 19 patients were collected for external validation. MPE was 0.206 μg/mL (not significantly different from zero) and MAPE was 0.99 μg/mL. Compared with trough levels, LSS using two samples or one sample at a different time provided better MPE, MAPE and correlation (R2) between the observed and LSS-predicted AUC. Conclusions: The population model that was developed showed significant association of voriconazole pharmacokinetics with post-operative time and liver function, and was able to predict an independent external dataset. Our observations suggested a need for intravenous administration of voriconazole in the immediate post-operative period before an oral dose can be administrated. LSS using one sample appeared to be sufficient for reasonable AUC estimation.",
keywords = "Antifungals, Dose-prediction, Liver-transplant, Pharmacokinetic-modelling, pharmacokinetics, Population-pharmacokinetics, Voriconazole",
author = "Kelong Han and Robert Bies and Heather Johnson and Blair Capitano and Raman Venkataramanan",
year = "2011",
doi = "10.2165/11538690-000000000-00000",
language = "English",
volume = "50",
pages = "201--214",
journal = "Clinical Pharmacokinetics",
issn = "0312-5963",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Population pharmacokinetic evaluation with external validation and bayesian estimator of voriconazole in liver transplant recipients

AU - Han, Kelong

AU - Bies, Robert

AU - Johnson, Heather

AU - Capitano, Blair

AU - Venkataramanan, Raman

PY - 2011

Y1 - 2011

N2 - Objectives: The objectives of this study were to evaluate the pharmacokinetics of voriconazole in liver transplant patients, probe covariate effects on voriconazole pharmacokinetics, externally validate the model and explore limited sampling strategies (LSSs) using Bayesian approaches. Methods: Full pharmacokinetic profiles were collected within one oral dosing interval from 13 liver transplant patients.Nonlinearmixed-effects pharmacokineticmodels were developed usingNONMEMsoftware. The final model was internally evaluated using bootstrapping and visual predictive check (VPC), and externally validated by predicting additional samples from different patients that were not used for model building. Maximum a posteriori Bayesian estimators were developed to predict the area under the plasma concentration-time curve (AUC) using the validated final model as the a priori model, actual dosing record and covariate values as the input, and a fewconcentrations (limited sampling) as feedback information (LSS).Mean prediction error (MPE) and mean absolute prediction error (MAPE) were calculated for external validation and LSS. Results: A one-compartment model with an absorption lag time (tlag) adequately described the data. Population estimates of total clearance after oral administration (CL/F) and volume of distribution after oral administration (Vd/F) were 7.92L/h and 248 L, respectively. Values of CL/F, V d/F and tlag decreased with post-operative time and converged to stable levels in about 7 post-operative days. CL/F significantly decreased with increased international normalized ratio. Co-administration of pantoprazole, race and alanine aminotransferase were also significantly associated with pharmacokinetic parameters but ultimately excluded in the final model. VPC showed that most of the data fell within the 90%prediction interval and were symmetrically distributed around the median. Additional 52 samples from 19 patients were collected for external validation. MPE was 0.206 μg/mL (not significantly different from zero) and MAPE was 0.99 μg/mL. Compared with trough levels, LSS using two samples or one sample at a different time provided better MPE, MAPE and correlation (R2) between the observed and LSS-predicted AUC. Conclusions: The population model that was developed showed significant association of voriconazole pharmacokinetics with post-operative time and liver function, and was able to predict an independent external dataset. Our observations suggested a need for intravenous administration of voriconazole in the immediate post-operative period before an oral dose can be administrated. LSS using one sample appeared to be sufficient for reasonable AUC estimation.

AB - Objectives: The objectives of this study were to evaluate the pharmacokinetics of voriconazole in liver transplant patients, probe covariate effects on voriconazole pharmacokinetics, externally validate the model and explore limited sampling strategies (LSSs) using Bayesian approaches. Methods: Full pharmacokinetic profiles were collected within one oral dosing interval from 13 liver transplant patients.Nonlinearmixed-effects pharmacokineticmodels were developed usingNONMEMsoftware. The final model was internally evaluated using bootstrapping and visual predictive check (VPC), and externally validated by predicting additional samples from different patients that were not used for model building. Maximum a posteriori Bayesian estimators were developed to predict the area under the plasma concentration-time curve (AUC) using the validated final model as the a priori model, actual dosing record and covariate values as the input, and a fewconcentrations (limited sampling) as feedback information (LSS).Mean prediction error (MPE) and mean absolute prediction error (MAPE) were calculated for external validation and LSS. Results: A one-compartment model with an absorption lag time (tlag) adequately described the data. Population estimates of total clearance after oral administration (CL/F) and volume of distribution after oral administration (Vd/F) were 7.92L/h and 248 L, respectively. Values of CL/F, V d/F and tlag decreased with post-operative time and converged to stable levels in about 7 post-operative days. CL/F significantly decreased with increased international normalized ratio. Co-administration of pantoprazole, race and alanine aminotransferase were also significantly associated with pharmacokinetic parameters but ultimately excluded in the final model. VPC showed that most of the data fell within the 90%prediction interval and were symmetrically distributed around the median. Additional 52 samples from 19 patients were collected for external validation. MPE was 0.206 μg/mL (not significantly different from zero) and MAPE was 0.99 μg/mL. Compared with trough levels, LSS using two samples or one sample at a different time provided better MPE, MAPE and correlation (R2) between the observed and LSS-predicted AUC. Conclusions: The population model that was developed showed significant association of voriconazole pharmacokinetics with post-operative time and liver function, and was able to predict an independent external dataset. Our observations suggested a need for intravenous administration of voriconazole in the immediate post-operative period before an oral dose can be administrated. LSS using one sample appeared to be sufficient for reasonable AUC estimation.

KW - Antifungals

KW - Dose-prediction

KW - Liver-transplant

KW - Pharmacokinetic-modelling

KW - pharmacokinetics

KW - Population-pharmacokinetics

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=79751482504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79751482504&partnerID=8YFLogxK

U2 - 10.2165/11538690-000000000-00000

DO - 10.2165/11538690-000000000-00000

M3 - Article

C2 - 21294597

AN - SCOPUS:79751482504

VL - 50

SP - 201

EP - 214

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

SN - 0312-5963

IS - 3

ER -